Delivery Order SPE2DB22D1017-SPE2DB25FG9ZZ
- Not listed
- The Defense Logistics Agency awarded a $2,395.34 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed price procurement with no set-aside designation. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this medical device delivery, which supports the federal government's...
- The Defense Logistics Agency awarded a delivery order valued at $1,138.73 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 31, 2025, and represents a child contract under AmerisourceBergen's broader pharmaceutical supply agreements with DLA. The products will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,793.30 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Gen 5 insulin infusion pods. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 4, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, supporting federal medical supply chain requirements. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $2,495.17 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 pods, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply needs. The award was issued on August 15, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $1,804.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pump pods. This non-set-aside competitive award was issued on July 29, 2025, with an ultimate completion date of July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a continuation of AmerisourceBergen's substantial role as a critical pharmaceutical and...
- The Defense Logistics Agency awarded a delivery order valued at $7,950.79 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 pods (Generation 5), 5-count units, with performance in Conshohocken, Pennsylvania and an ultimate completion date of July 29, 2025. This is a firm fixed-price delivery order issued under a non-set-aside competitive process, representing a child contract under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Gen 5 insulin infusion pods valued at $1,222.32. This competitive, firm fixed-price delivery order was issued on August 7, 2025, with an ultimate completion date of August 8, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical and medical...
- The Defense Logistics Agency awarded a $3,951.77 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 pods (Generation 5), with a completion date of July 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child order under AmerisourceBergen's larger contract vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a $2,174.98 firm fixed price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 pods, with performance in Conshohocken, Pennsylvania and completion by July 21, 2025. This non-set-aside competitive award was issued on July 18, 2025, and represents a child delivery order under AmerisourceBergen's larger contract vehicle with DLA Troop Support Medical. The delivery order addresses federal diabetes management and continuous glucose...
- The Defense Logistics Agency (DLA) awarded a $17,144.30 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. This competitively awarded, firm fixed-price contract is scheduled for completion by July 31, 2025, with performance taking place at the contractor's Conshohocken, Pennsylvania facility. The delivery order carries no set-aside designation and represents a continuation of the company's extensive medical supply support to federal...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG9ZZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,240.92 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. This competitive award, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, represents a firm fixed-price transaction with no set-aside designation. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, supporting the company's role as a critical federal pharmaceutical and medical device distributor. This delivery order is executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive $999.99 billion global pharmaceutical support vehicle valued through December 2026. The IDC serves as the primary procurement mechanism enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical devices to military healthcare systems, the Defense Health Agency, U.S. Coast Guard, and other federal health organizations. The OmniPod 5 pods represent specialized diabetes management technology within the company's extensive portfolio of brand-name medications, generic drugs, vaccines, and medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 8/18/25 |